VANDA PHARMACEUTICALS INC. Number of Reportable Segments
VANDA PHARMACEUTICALS INC. (VNDA) reported Number of Reportable Segments of 1 segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-06
- VANDA PHARMACEUTICALS INC. number of reportable segments for the quarter ending 2015-03-31 was 1.00 Segment.
- VANDA PHARMACEUTICALS INC. number of reportable segments for fiscal 2019 was 1.00 Segment.
- VANDA PHARMACEUTICALS INC. number of reportable segments for fiscal 2016 was 1.00 Segment, a 0.00% change from fiscal 2015.
- VANDA PHARMACEUTICALS INC. number of reportable segments for fiscal 2015 was 1.00 Segment.
Segment
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2019-12-31 | 1.00 Segment 10-K · filed 2020-02-26 | |||
| 2016-12-31 | 1.00 Segment 10-K · filed 2017-02-17 | |||
| 2015-12-31 | 1.00 Segment 10-K · filed 2016-02-12 | |||
| 2015-09-30 | 1.00 Segment 10-Q · filed 2015-11-04 | |||
| 2015-06-30 | 1.00 Segment 10-Q · filed 2015-07-31 | |||
| 2015-03-31 | 1.00 Segment 10-Q · filed 2015-05-07 |
segment
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 segment 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 1.00 segment 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 1.00 segment 10-K · filed 2026-02-12 | |||
| 2025-09-30 | 1.00 segment 10-Q · filed 2025-10-30 | |||
| 2025-06-30 | 1.00 segment 10-Q · filed 2025-07-31 | |||
| 2025-03-31 | 1.00 segment 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | 1.00 segment 10-K · filed 2025-02-14 | |||
| 2024-09-30 | 1.00 segment 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | 1.00 segment 10-Q · filed 2024-08-01 | |||
| 2024-03-31 | 1.00 segment 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | 1.00 segment 10-K · filed 2024-02-08 | |||
| 2023-09-30 | 1.00 segment 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | 1.00 segment 10-Q · filed 2023-07-28 | |||
| 2023-03-31 | 1.00 segment 10-Q · filed 2023-05-03 | |||
| 2022-12-31 | 1.00 segment 10-K · filed 2023-02-09 | |||
| 2022-09-30 | 1.00 segment 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | 1.00 segment 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | 1.00 segment 10-Q · filed 2022-05-06 | |||
| 2021-12-31 | 1.00 segment 10-K · filed 2022-02-24 | |||
| 2020-12-31 | 1.00 segment 10-K · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |